达安基因
(002030)
| 流通市值：88.98亿 | | | 总市值：88.98亿 |
| 流通股本：14.03亿 | | | 总股本：14.03亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 591,050,057.91 | 400,381,368.24 | 198,307,676.45 | 1,180,897,087.04 |
| 营业收入 | 591,050,057.91 | 400,381,368.24 | 198,307,676.45 | 1,180,897,087.04 |
| 利息收入 | 0 | 0 | 0 | 0 |
| 已赚保费 | 0 | 0 | 0 | 0 |
| 手续费及佣金收入 | 0 | 0 | 0 | 0 |
| 二、营业总成本 | 695,779,975.01 | 454,312,338.72 | 207,951,519.66 | 1,133,440,757.45 |
| 营业成本 | 354,750,208.8 | 235,349,667.91 | 87,581,209.69 | 584,929,093.72 |
| 利息支出 | 0 | 0 | 0 | 0 |
| 手续费及佣金支出 | 0 | 0 | 0 | 0 |
| 退保金 | 0 | 0 | 0 | 0 |
| 赔付支出净额 | 0 | 0 | 0 | 0 |
| 提取保险合同准备金净额 | 0 | 0 | 0 | 0 |
| 保单红利支出 | 0 | 0 | 0 | 0 |
| 分保费用 | 0 | 0 | 0 | 0 |
| 税金及附加 | 4,212,451.3 | 2,786,935.4 | 1,223,206.73 | 9,781,719.09 |
| 销售费用 | 105,810,189.55 | 62,995,789.03 | 25,419,046.72 | 172,833,278.42 |
| 管理费用 | 111,681,235.85 | 68,056,335.76 | 53,414,419.96 | 138,313,374 |
| 研发费用 | 167,134,295.16 | 118,905,329.41 | 56,401,238.8 | 302,332,171.04 |
| 财务费用 | -47,808,405.65 | -33,781,718.79 | -16,087,602.24 | -74,748,878.82 |
| 其中:利息费用 | 5,742,298.28 | 4,457,798.91 | 2,157,240.1 | 10,042,125.86 |
| 其中:利息收入 | 53,386,221.47 | 36,752,757.39 | 18,454,705.45 | 83,099,536.1 |
| 加:公允价值变动收益 | -119,224,149.48 | -306,861,205.58 | -365,572,891.12 | 435,690,646.25 |
| 加:投资收益 | -130,108,689.2 | -29,960,605.45 | -22,096,061.02 | -26,246,655.88 |
| 净敞口套期收益 | 0 | 0 | 0 | 0 |
| 汇兑收益 | 0 | 0 | 0 | 0 |
| 资产处置收益 | 2,077,739.9 | -1,160,087.84 | -617,064.09 | -3,039,675.21 |
| 资产减值损失(新) | -113,954.43 | -85,860.45 | 54,409.17 | -262,753,953.87 |
| 信用减值损失(新) | -247,295,765.62 | -107,629,286.33 | -48,499,214.15 | -153,689,485.16 |
| 其他收益 | 32,632,643.94 | 24,890,695.65 | 13,067,801.74 | 84,204,656.3 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -566,762,091.99 | -474,737,320.48 | -433,306,862.68 | 121,621,862.02 |
| 加:营业外收入 | 436,836.52 | 128,416.31 | 126,532.41 | 1,889,579.2 |
| 减:营业外支出 | 1,552,357.49 | 1,406,707.59 | 887,742.33 | 9,975,491.46 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -567,877,612.96 | -476,015,611.76 | -434,068,072.6 | 113,535,949.76 |
| 减:所得税费用 | -66,376,049.48 | -78,369,791.08 | -72,927,188.7 | 41,804,363.65 |
| 六、净利润 | -501,501,563.48 | -397,645,820.68 | -361,140,883.9 | 71,731,586.11 |
| 持续经营净利润 | -501,501,563.48 | -397,645,820.68 | -361,140,883.9 | 71,731,586.11 |
| 终止经营净利润 | 0 | 0 | 0 | 0 |
| 归属于母公司股东的净利润 | -502,719,727.25 | -399,219,058.46 | -363,290,638.81 | 104,659,624.06 |
| 少数股东损益 | 1,218,163.77 | 1,573,237.78 | 2,149,754.91 | -32,928,037.95 |
| (一)基本每股收益 | -0.36 | -0.28 | -0.26 | 0.07 |
| (二)稀释每股收益 | -0.36 | -0.28 | -0.26 | 0.07 |
| 八、其他综合收益 | 125,820.15 | 485,109.64 | 220,519.57 | -867,076.31 |
| 归属于母公司股东的其他综合收益 | 162,725.34 | 445,072.4 | 223,605.54 | -1,067,187.13 |
| 九、综合收益总额 | -501,375,743.33 | -397,160,711.04 | -360,920,364.33 | 70,864,509.8 |
| 归属于母公司股东的综合收益总额 | -502,557,001.91 | -398,773,986.06 | -363,067,033.27 | 103,592,436.93 |
| 归属于少数股东的综合收益总额 | 1,181,258.58 | 1,613,275.02 | 2,146,668.94 | -32,727,927.13 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-30 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |